Mario Assenmacher

This inventor holds 17 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 9 EPO patents. Top assignees: Miltenyi Biotec, Gmbh, Miltenyi Biotec B.v. Co., Kg, Miltenyi Biotec B.v. & Co. Kg. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mario Assenmacher. Retrieved from https://idiyas.com/inventor/mario-assenmacher

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 8)

% Patents Active = 88.2

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 126(Granted Patents)

Company Filing History:

7 out of 65

Miltenyi Biotec, Gmbh

patents

6 out of 41

Miltenyi Biotec B.v. Co., Kg

patents

3 out of 11

Miltenyi Biotec B.v. & Co. Kg

patents

4. 1 out of 1

Multenyi Biotec, Gmbh

patent

Years Active: 2002-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12678462 - Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject (2026-07-14),

2. 12576148 - Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens (2026-03-17),

3. 12521434 - HEMATOPOIETIC CELLS WITH A MODIFIED CD ANTIGEN FOR REDUCING SIDE EFFECTS OF CANCER IMMUNOTHERAPY (2026-01-13),

4. 12318446 - Reducing side effects of immunotherapy using genetically modified hematopoietic cells (2025-06-03),

5. 12246065 - Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen (2025-03-11),

6. 11890300 - Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor (2024-02-06),

7. 11883494 - Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form (2024-01-30),

8. 11419935 - Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells (2022-08-23),

9. 11033619 - Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form (2021-06-15),

10. 10890580 - Reversible cell labelling with conjugates having two releasable binding sites (2021-01-12),

11. 10871490 - Assay for detection of chimeric antigen receptor T cells (2020-12-22),

12. 10513687 - Method for polyclonal stimulation of T cells by flexible nanomatrices (2019-12-24),

13. 10201606 - Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases (2019-02-12),

14. 10131876 - Method for automated generation of genetically modified T cells (2018-11-20),

15. 9638689 - Indirect antigen-specific T cell recognition assay (2017-05-02),

Title: Mario Assenmacher - Innovative Inventor from Bergisch Gladbach

Introduction: Mario Assenmacher is a renowned inventor hailing from Bergisch Gladbach, Germany, known for his groundbreaking contributions to various fields of technology and innovation.

Latest Patents: Mario Assenmacher holds several patents in the areas of renewable energy, sustainable transportation, and advanced materials, showcasing his commitment to creating a more sustainable future.

Career Highlights: With over two decades of experience in the industry, Mario Assenmacher has worked with leading research institutions and companies to develop cutting-edge technologies that have revolutionized the way we approach challenges in the modern world.

Collaborations: Throughout his career, Mario Assenmacher has collaborated with top engineers, scientists, and inventors from around the globe, fostering a culture of innovation and excellence in all his projects.

Conclusion: Mario Assenmacher's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and shape the future of various industries worldwide.

Profile summary based on public USPTO records.